Ocular　angiogenesis,　the　process　of　neovascularization　in　the　eye,　can　occur　in　various　parts　of　the　eye　and　lead　to　severe　visual　impairment.　While　anti-vascular　endothelial　growth　factor　(VEGF)　antibody　agents　remain　the　primary　treatment　for　this　condition,　their　clinical　efficacy　is　compromised　by　the　requirement　for　repeated　intravitreal　injections　-　an　invasive　procedure　associated　with　cumulative　risks　of　ocular　complications　and　patient　non-compliance.　This　manuscript　reviews　the　emerging　utilization　of　silicon　nanoneedles　(Si　NNs)　as　a　novel　drug　delivery　platform　to　address　these　critical　challenges.　We　discuss　the　unique　characteristics　of　Si　NNs　that　render　them　suitable　for　ocular　anti-VEGF　therapy　and　summarize　the　current　applications　of　this　approach　in　ocular　anti-VEGF　treatment　across　diverse　ocular　disease　models.　The　controlled,　long-term,　and　sustained　drug　release,　in　conjunction　with　the　minimal　invasiveness,　renders　Si　NNs　a　promising　technique　for　ocular　anti-VEGF　treatment.　©　2025　IEEE.